Short description: Human protein-coding gene on chromosome 9
Generic protein structure example
Tyrosine-protein kinase ABL1 also known as ABL1 is a protein that, in humans, is encoded by the ABL1gene (previous symbol ABL) located on chromosome 9.[1] c-Abl is sometimes used to refer to the version of the gene found within the mammalian genome, while v-Abl refers to the viral gene, which was initially isolated from the Abelson murine leukemia virus.[2]
The ABL1proto-oncogene encodes a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response such as DNA repair.[3][4][5][6] Activity of ABL1 protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9;22) translocation results in the head-to-tail fusion of the BCR and ABL1 genes, leading to a fusion gene present in many cases of chronic myelogenous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1. The ABL1 gene is expressed as either a 6- or a 7-kb mRNA transcript, with alternatively spliced first exons spliced to the common exons 2–11.[7]
Mutations in the ABL1 gene are associated with chronic myelogenous leukemia (CML). In CML, the gene is activated by being translocated within the BCR (breakpoint cluster region) gene on chromosome 22. This new fusion gene, BCR-ABL, encodes an unregulated, cytoplasm-targeted tyrosine kinase that allows the cells to proliferate without being regulated by cytokines. This, in turn, allows the cell to become cancerous.
This gene is a partner in a fusion gene with the BCR gene in the Philadelphia chromosome, a characteristic abnormality in chronic myelogenous leukemia (CML) and rarely in some other leukemia forms. The BCR-ABL transcript encodes a tyrosine kinase, which activates mediators of the cell cycle regulation system, leading to a clonal myeloproliferative disorder. The BCR-ABL protein can be inhibited by various small molecules. One such inhibitor is imatinib mesylate, which occupies the tyrosine kinase domain and inhibits BCR-ABL's influence on the cell cycle. Second generation BCR-ABL tyrosine-kinase inhibitors are also under development
to inhibit BCR-ABL mutants resistant to imatinib.[8]
↑"Lymphosarcoma: virus-induced thymic-independent disease in mice". Cancer Research30 (8): 2213–22. August 1970. PMID4318922.
↑"Mutational analyses of the human Rad51-Tyr315 residue, a site for phosphorylation in leukaemia cells". Genes to Cells9 (9): 781–90. September 2004. doi:10.1111/j.1365-2443.2004.00772.x. PMID15330855.
↑"BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP". Carcinogenesis32 (1): 27–34. January 2011. doi:10.1093/carcin/bgq216. PMID20974687.
↑"Abl interactor 1 promotes tyrosine 296 phosphorylation of mammalian enabled (Mena) by c-Abl kinase". J. Biol. Chem.278 (24): 21685–92. June 2003. doi:10.1074/jbc.M301447200. PMID12672821.
↑"Isolation and characterization of e3B1, an eps8 binding protein that regulates cell growth". Oncogene14 (2): 233–41. January 1997. doi:10.1038/sj.onc.1200822. PMID9010225.
↑"Isolation of hNap1BP which interacts with human Nap1 (NCKAP1) whose expression is down-regulated in Alzheimer's disease". Gene271 (2): 159–69. June 2001. doi:10.1016/S0378-1119(01)00521-2. PMID11418237.
↑ 12.012.1"Functional interaction between the c-Abl and Arg protein-tyrosine kinases in the oxidative stress response". J. Biol. Chem.278 (15): 12961–7. April 2003. doi:10.1074/jbc.M300058200. PMID12569093.
↑"Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity". Genes Dev.9 (21): 2569–82. November 1995. doi:10.1101/gad.9.21.2569. PMID7590236.
↑ 14.014.1"Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl". J. Biol. Chem.274 (18): 12748–52. April 1999. doi:10.1074/jbc.274.18.12748. PMID10212258.
↑ 16.016.1"Telomeric protein Pin2/TRF1 as an important ATM target in response to double strand DNA breaks". J. Biol. Chem.276 (31): 29282–91. August 2001. doi:10.1074/jbc.M011534200. PMID11375976.
↑"p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene". J. Biol. Chem.271 (41): 25198–203. October 1996. doi:10.1074/jbc.271.41.25198. PMID8810278.
↑"Evidence that SH2 domains promote processive phosphorylation by protein-tyrosine kinases". Curr. Biol.5 (3): 296–305. March 1995. doi:10.1016/S0960-9822(95)00060-1. PMID7780740.
↑"Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr". Cancer Res.63 (2): 298–303. January 2003. PMID12543778.
↑"BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner". Cell66 (1): 161–71. July 1991. doi:10.1016/0092-8674(91)90148-R. PMID1712671.
↑"Catalase activity is regulated by c-Abl and Arg in the oxidative stress response". J. Biol. Chem.278 (32): 29667–75. August 2003. doi:10.1074/jbc.M301292200. PMID12777400.
↑ 24.024.1"Regulation of Cbl phosphorylation by the Abl tyrosine kinase and the Nck SH2/SH3 adaptor". Oncogene20 (30): 4058–69. July 2001. doi:10.1038/sj.onc.1204528. PMID11494134.
↑ 26.026.126.2"Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites". Genes Dev.8 (7): 783–95. April 1994. doi:10.1101/gad.8.7.783. PMID7926767.
↑"Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation". Blood89 (1): 297–306. January 1997. doi:10.1182/blood.V89.1.297. PMID8978305.
↑"Differential interaction of Crkl with Cbl or C3G, Hef-1, and gamma subunit immunoreceptor tyrosine-based activation motif in signaling of myeloid high affinity Fc receptor for IgG (Fc gamma RI)". J. Immunol.161 (10): 5555–63. November 1998. doi:10.4049/jimmunol.161.10.5555. PMID9820532.
↑"Multiple signaling interactions of Abl and Arg kinases with the EphB2 receptor". Oncogene20 (30): 3995–4006. July 2001. doi:10.1038/sj.onc.1204524. PMID11494128.
↑"Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases". J. Biol. Chem.278 (41): 39609–14. October 2003. doi:10.1074/jbc.M305770200. PMID12893824.
↑"Human GRB-IRbeta/GRB10. Splice variants of an insulin and growth factor receptor-binding protein with PH and SH2 domains". J. Biol. Chem.272 (5): 2659–67. January 1997. doi:10.1074/jbc.272.5.2659. PMID9006901.
↑"Regulation of the rapamycin and FKBP-target 1/mammalian target of rapamycin and cap-dependent initiation of translation by the c-Abl protein-tyrosine kinase". J. Biol. Chem.275 (15): 10779–87. April 2000. doi:10.1074/jbc.275.15.10779. PMID10753870.
↑"The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr". J. Biol. Chem.272 (52): 33260–70. December 1997. doi:10.1074/jbc.272.52.33260. PMID9407116.
↑"Direct interaction of nerve growth factor receptor, TrkA, with non-receptor tyrosine kinase, c-Abl, through the activation loop". FEBS Lett.469 (1): 72–6. March 2000. doi:10.1016/S0014-5793(00)01242-4. PMID10708759.
↑"Cytoskeletal protein PSTPIP1 directs the PEST-type protein tyrosine phosphatase to the c-Abl kinase to mediate Abl dephosphorylation". Mol. Cell6 (6): 1413–23. December 2000. doi:10.1016/S1097-2765(00)00138-6. PMID11163214.
↑"Interaction of BCR-ABL with the retinoblastoma protein in Philadelphia chromosome-positive cell lines". Int. J. Hematol.65 (2): 115–21. February 1997. doi:10.1016/S0925-5710(96)00539-7. PMID9071815.
↑"A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle". Cell75 (4): 779–90. November 1993. doi:10.1016/0092-8674(93)90497-E. PMID8242749.
↑"The kinase activity of c-Abl but not v-Abl is potentiated by direct interaction with RFXI, a protein that binds the enhancers of several viruses and cell-cycle regulated genes". Oncogene16 (14): 1779–88. April 1998. doi:10.1038/sj.onc.1201708. PMID9583676.
↑"A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells". Blood93 (8): 2707–20. April 1999. doi:10.1182/blood.V93.8.2707. PMID10194451.
↑"ArgBP2, a multiple Src homology 3 domain-containing, Arg/Abl-interacting protein, is phosphorylated in v-Abl-transformed cells and localized in stress fibers and cardiocyte Z-disks". J. Biol. Chem.272 (28): 17542–50. July 1997. doi:10.1074/jbc.272.28.17542. PMID9211900.
↑ 54.054.1"Identification of a candidate human spectrin Src homology 3 domain-binding protein suggests a general mechanism of association of tyrosine kinases with the spectrin-based membrane skeleton". J. Biol. Chem.273 (22): 13681–92. May 1998. doi:10.1074/jbc.273.22.13681. PMID9593709.
↑"Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway". J. Biol. Chem.277 (14): 12437–45. April 2002. doi:10.1074/jbc.M112397200. PMID11790798.
↑"The intranuclear localization and function of YT521-B is regulated by tyrosine phosphorylation". Hum. Mol. Genet.13 (15): 1535–49. August 2004. doi:10.1093/hmg/ddh167. PMID15175272.
↑"Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression". Cancer Cell13 (6): 496–506. June 2008. doi:10.1016/j.ccr.2008.04.018. PMID18538733.
"Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells". Int. J. Hematol.76 (1): 35–43. 2002. doi:10.1007/BF02982716. PMID12138893.
"Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature". Cancer Genet. Cytogenet.138 (2): 139–42. 2002. doi:10.1016/S0165-4608(02)00609-X. PMID12505259.
2o88: Crystal structure of the N114A mutant of ABL-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions